Akademska digitalna zbirka SLovenije - logo
E-viri
Celotno besedilo
Recenzirano Odprti dostop
  • Genetic Diagnosis of Retino...
    Gerrish, Amy; Mashayamombe-Wolfgarten, Chipo; Stone, Edward; Román-Montañana, Claudia; Abbott, Joseph; Jenkinson, Helen; Millen, Gerard; Gurney, Sam; McCalla, Maureen; Staveley, Sarah-Jane; Kainth, Anu; Kirk, Maria; Bowen, Claire; Cavanagh, Susan; Bunstone, Sancha; Carney, Megan; Mohite, Ajay; Clokie, Samuel; Reddy, M Ashwin; Foster, Alison; Allen, Stephanie; Parulekar, Manoj; Cole, Trevor

    Cancers, 2024-Apr-19, Letnik: 16, Številka: 8
    Journal Article

    The identification of somatic variation is crucial to confirm the heritability of retinoblastoma. We and others have previously shown that, when tumour DNA is unavailable, cell-free DNA (cfDNA) derived from aqueous humour (AH) can be used to identify somatic pathogenic variation. Here we report pathogenic variant detection, as well as cfDNA concentration in an extended cohort of 75 AH samples from 68 patients. We show cfDNA concentration is highly variable and significantly correlated with the collection point of the AH. Cell-free DNA concentrations above 5 pg/µL enabled the detection of 93% of known or expected pathogenic variants. In AH samples collected during intravitreal chemotherapy treatment (Tx), the yield of cfDNA above 5 pg/µL and subsequent variant detection was low (≤46%). However, AH collected by an anterior chamber tap after one to three cycles of primary chemotherapy (Dx1+) enabled the detection of 75% of expected pathogenic variants. Further limiting our analysis to Dx1+ samples taken after ≤2 cycles (Dx ≤ 2) provided measurable levels of cfDNA in all cases, and a subsequent variant detection rate of 95%. Early AH sampling is therefore likely to be important in maximising cfDNA concentration and the subsequent detection of somatic pathogenic variants in retinoblastoma patients undergoing conservative treatment.